enVVeno Medical Corporation (NVNO) 是一家上市公司 属于 医疗保健 板块，经营于 Medical - Devices 行业. 公司总部位于 Irvine, CA, 美国. 现任CEO为 Robert A. Berman.
NVNO 拥有 IPO日期为 2018-05-31, 37 名全职员工, 在 NASDAQ Capital Marke, 市值为 $186.15K.
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
